Idiopathic pulmonary fibrosis (IPF) remains a disease with poor survival. The pathogenesis
is complex and encompasses multiple molecular pathways. The first-generation antifibrotics …

Idiopathic pulmonary fibrosis (IPF) is a devastating condition with a 5‐year survival of
approximately 20%. The disease primarily occurs in elderly patients. IPF is a highly …

Idiopathic pulmonary fibrosis (IPF) is a chronic progressive disease of unknown cause
characterized by relentless scarring of the lung parenchyma leading to reduced quality of life …

Idiopathic pulmonary fibrosis (IPF) is a progressive devastating lung disease with substantial
morbidity. It is associated with cough, dyspnea and impaired quality of life. If left untreated …

ABSTRACT Idiopathic Pulmonary Fibrosis (IPF) is a progressive, fatal lung disorder of
unknown cause with a highly variable and unpredictable clinical course. The advances …

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fibrosing interstitial lung
disease, characterised by progressive scarring of the lung and associated with a high …

Idiopathic pulmonary fibrosis (IPF) is a deadly disease with a median survival of
approximately three years in historical cohorts. Despite increased knowledge of disease …

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive diffuse parenchymal lung
disease of unknown origin, with a mortality rate exceeding that of many cancers. The …

Idiopathic pulmonary fibrosis (IPF) is an aging-associated, recalcitrant lung disease with
historically limited therapeutic options. The recent approval of two drugs, pirfenidone and …

Idiopathic pulmonary fibrosis (IPF) is a chronic progressive lung disease with poor survival.
Recent studies have improved understanding of IPF and new discoveries have led to novel …